Verastem Revenue

Verastem had revenue of $10.00M in the twelve months ending March 31, 2025. In the year 2024, Verastem had annual revenue of $10.00M.

Revenue (ttm)

$10.00M

Revenue Growth

n/a

P/S Ratio

20.42

Revenue / Employee

$128,205

Employees

Market Cap

263.76M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	10.00M	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	2.60M	543.00K	26.45%
Dec 31, 2021	2.05M	-86.46M	-97.68%
Dec 31, 2020	88.52M	71.06M	407.08%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	410.06B
Johnson & Johnson	89.33B
Merck & Co.	63.92B
AbbVie	57.37B
AstraZeneca	54.98B
Novartis AG	53.22B
Eli Lilly and Company	49.00B
Novo Nordisk	43.92B

Revenue Rankings

VSTM News

3 days ago - Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer - Business Wire
7 days ago - Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha
9 days ago - Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - Business Wire
4 weeks ago - Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor - Business Wire
5 weeks ago - Verastem Oncology to Present at the Jefferies Global Healthcare Conference - Business Wire
6 weeks ago - Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma - Business Wire
6 weeks ago - Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - Business Wire
7 weeks ago - Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire

More News